Evidence map›Paper›PMID 31738768›Full record

ArticlePLoS neglected tropical diseases2019

Cryptococcus genetic diversity and mixed infections in Ivorian HIV patients: A follow up study.

Fulgence Kondo Kassi, Pascal Drakulovski, Virginie Bellet, Frédéric Roger, Amélie Chabrol, Donika Krasteva, Adama Doumbia, Roland Landman, Aka Kakou, Jacques Reynes and 3 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Involvement of CD146 in theInfection and immunity · 2025
    Article
  4. Article
  5. Antifungal Resistance in Cryptococcal Infections.Pathogens (Basel, Switzerland) · 2024
    Review
  6. Article
  7. Genotyping Analysis ofJournal of fungi (Basel, Switzerland) · 2023
    Article
  8. Article
  9. Exposure ofPathogens (Basel, Switzerland) · 2023
    Article
  10. Article
  11. Journal of fungi (Basel, Switzerland) · 2022
    Article
  12. Journal of fungi (Basel, Switzerland) · 2022
    Review
  13. Article
  14. Review
  15. Journal of fungi (Basel, Switzerland) · 2021
    Article
  16. Critical reviews in microbiology · 2021
    Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Fulgence Kondo KassiUniversité Félix Houphouet-Boigny, Unité des Sciences Pharmaceutiques et Biologiques, Abidjan, Côte d'Ivoire.
Pascal DrakulovskiLaboratoire de Parasitologie et Mycologie Médicale, IRD UMI 233, INSERM U1175, Université de Montpellier, Unité TransVIHMI, Montpellier, France.ORCID 0000-0002-6808-2693
Virginie BelletLaboratoire de Parasitologie et Mycologie Médicale, IRD UMI 233, INSERM U1175, Université de Montpellier, Unité TransVIHMI, Montpellier, France.
Frédéric RogerLaboratoire de Parasitologie et Mycologie Médicale, IRD UMI 233, INSERM U1175, Université de Montpellier, Unité TransVIHMI, Montpellier, France.
Amélie ChabrolService de Maladies Infectieuses et Tropicales, CH Sud Francilien, Corbeil, France.
Donika KrastevaLaboratoire de Parasitologie et Mycologie Médicale, IRD UMI 233, INSERM U1175, Université de Montpellier, Unité TransVIHMI, Montpellier, France.
Adama DoumbiaUniversité Félix Houphouet-Boigny, Unité des Sciences Pharmaceutiques et Biologiques, Abidjan, Côte d'Ivoire.
Roland LandmanInstitut de Médecine et Epidémiologie Appliquée (IMEA), Fondation Léon M'Ba, Paris, France.
Aka KakouService des Maladies Infectieuses et Tropicales, CHU Treichville, Abidjan, Côte d'Ivoire.
Jacques ReynesCHU Gui de Chauliac, Service des Maladies Infectieuses et Tropicales, IRD UMI 233, INSERM U1175, Université de Montpellier, Unité TransVIHMI, Montpellier, France.
Eric DelaporteTransVIHMI/INSERM1175, Institut de Recherche pour le Développement (IRD) and University of Montpellier, Montpellier, France.
Hervé Eby Ignace MenanDiagnostic and Research Center on AIDS and Other Infectious Diseases (CeDReS), Abidjan, Côte d'Ivoire.
Sébastien BertoutLaboratoire de Parasitologie et Mycologie Médicale, IRD UMI 233, INSERM U1175, Université de Montpellier, Unité TransVIHMI, Montpellier, France.
Inserm · FRUniversité Félix Houphouët-Boigny · CIUniversity Hospital Medical Center at Treichville · CIAgropolis International · FRUniversité Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genetic diversity analyses were performed by sero-genotyping and multi-locus sequence typing on 252 cryptococcal isolates from 13 HIV-positive Ivorian patients followed-up for cryptococcal meningitis. Antifungal susceptibility analyses were performed according to the CLSI M27A3 method. The majority (67.8%) of the isolates belonged to the Cryptococcus neoformans (serotype A) species complex, with 93% being VNI and 7% being VNII. Cryptococcus deuterogattii VGII (serotype B) represented 16.7% of the strains, while C. neoformans/C. deneoformans VNIII (serotype AD) hybrids accounted for 15.1% of the strains. One strain (0.4%) was not identifiable. Nine different sequence types (STs 5, 6, 23, 40, 93, 207, 311, and a new ST; 555) were identified in the C. neoformans population, while the C. deuterogattii population comprised the single ST 173. The distribution of the strains showed that, while the majority of patients (9/13) harboured a single sequence type, 4 patients showed mixed infections. These patients experienced up to 4 shifts in strain content either at the species and/or ST level during their follow-up. This evolution of diversity over time led to the co-existence of up to 3 different Cryptococcus species and 4 different ST within the same individual during the course of infection. Susceptibility testing showed that all strains were susceptible to amphotericin B while 3.6% of them had a none-wild type phenotype to 5-flucytosine. Concerning fluconazole, 2.9% of C.neoformans serotype A strains and 2.4% of C. deuterogattii had also respectively a none-wild type phenotype to this molecule. All C. neoformans x C. deneoformans serotype AD hybrids had however a wild type phenotype to fluconazole. The present study showed that mixed infections exist and could be of particular importance for care outcomes. Indeed, (i) the different Cryptococcus species are known to exhibit different virulence and different susceptibility patterns to antifungal drugs and (ii) the strains genetic diversity within the samples may influence the susceptibility to antifungal treatment.

Indexed as

CoinfectionGenetic VariationAdultAmphotericin BAntifungal AgentsCryptococcosisCryptococcusCryptococcus neoformansFemaleFluconazoleFlucytosineFollow-Up StudiesHIV InfectionsHumansMaleMeningitis, CryptococcalAmphotericin BAntifungal AgentsFluconazoleFlucytosine

Identifiers

PMID31738768
PMCPMC6886875
OpenAlexW2984331479

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.